Akebia Therapeutics, Inc. SEC filings AKBA
Akebia Therapeutics, Inc. has 886 filings in SEC EDGAR's recent list, going back to Apr 8, 2011. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 28, 2026 | Apr 28, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 15, 2026 | Apr 15, 2026 |
| DEFA14A | Additional proxy material | Apr 29, 2025 | — |
| DEF 14A | Proxy statement | Apr 29, 2025 | Apr 29, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Apr 25, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | — |
| DEFA14A | Additional proxy material | Apr 21, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 14, 2023 | — |
| DEFA14A | Additional proxy material | Apr 11, 2023 | — |
| DEFA14A | Additional proxy material | Mar 31, 2023 | — |
| DEFA14A | Additional proxy material | Mar 27, 2023 | — |
| DEFA14A | Additional proxy material | Mar 27, 2023 | — |
| DEFA14A | Additional proxy material | Mar 27, 2023 | — |
| DEFA14A | Additional proxy material | Mar 24, 2023 | — |
| DEF 14A | Proxy statement | Mar 1, 2023 | Apr 11, 2023 |
| PRE 14A | Preliminary proxy statement | Feb 17, 2023 | Apr 11, 2023 |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 2, 2021 |
| DEFA14A | Additional proxy material | May 21, 2020 | — |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Jun 5, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2020 | Jun 4, 2020 |
| DEFA14A | Additional proxy material | May 9, 2019 | — |
| DEFA14A | Additional proxy material | Apr 26, 2019 | — |
| DEF 14A | Proxy statement | Apr 26, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Apr 30, 2018 | — |
| DEF 14A | Proxy statement | Apr 30, 2018 | Jun 14, 2018 |
| DEFA14A | Additional proxy material | May 1, 2017 | — |
| DEF 14A | Proxy statement | May 1, 2017 | Jun 15, 2017 |
| DEFA14A | Additional proxy material | Apr 29, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 16, 2016 |
| DEFA14A | Additional proxy material | Apr 30, 2015 | — |
| DEF 14A | Proxy statement | Apr 30, 2015 | Jun 10, 2015 |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AKBA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1517022
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.